MSK researchers develop new open-source method to improve decoding of single-cell data

Researchers at Memorial Sloan Kettering Cancer Center (MSK) have developed a new open-source computational method, dubbed Spectra, which improves the analysis of single-cell transcriptomic data.

By guiding data analysis in a unique way, Spectra can offer new insights into the complex interplay between cells — like the interactions between cancer cells and immune cells, which are critical to improving immunotherapy treatments.

The team’s approach and findings were recently published in Nature Biotechnology, one of the most influential journals in the field.

Spectra, the researchers note, can cut through technical “noise” to identify functionally relevant gene expression programs, including those that are novel or highly specific to a particular biological context.

The algorithm is well suited to study data from large patient cohorts and to suss out clinically meaningful patient characteristics, the MSK team writes in a research briefing that accompanies the study, adding that Spectra is ideal for identifying biomarkers and drug targets in the burgeoning field of immuno-oncology.

Additionally, the MSK team has made Spectra freely available to researchers around the world.

“I’m trained as a computer scientist,” says study senior author Dana Pe’er, PhD, who chairs the Computational and Systems Biology Program at MSK’s Sloan Kettering Institute. “Every single tool I build, I strive to make robust so it can be used in many contexts, not just one. I also try and make them as accessible as possible.”

“I’m happy to discover new biology,” she continues. “And I’m just as happy — perhaps happier — to build a foundational tool that can be used by the wider community to make many biological discoveries.”

Along with researchers at MSK, teams from several institutions are already using Spectra to study a variety of diseases, Dr. Pe’er adds.

The Single-Cell Revolution

Over the past decade, the “single-cell revolution” has transformed human understanding of health and disease. Single-cell technologies allow scientists to study the individual cells in a tissue sample or set of samples — a tumor, for example — and see not only the variety of cell types that are present (such as cancer cells versus various types of immune cells) but also which genes are active in each cell, shedding new light on cell states and cell interactions. The technology has fostered new understandings about how cells adapt and respond to changing conditions in health and disease — including the development of resistance to cancer treatments.

The problem is that the mind-boggling amount of data generated by single-cell methods is challenging to sift through and correctly interpret. This is particularly true when trying to look at gene programs — genes that work together to accomplish a particular task —that are active across multiple cell types in a tissue, Dr. Pe’er explains.

“This is especially important for studying the interactions between cancer cells and immune cells, which involve highly overlapping gene programs,” she says. “This causes some serious statistical problems that can lead to incredibly misleading results.”

The team Dr. Pe’er assembled — led by co-first authors Russell Kunes, a doctoral student trained in statistics, and Thomas Walle, MD, a physician-scientist with expertise in immuno-oncology — not only developed the improved method for guiding the data analysis, but they also created a user-friendly interface to facilitate its adoption by other scientists.

“Our desire to develop an improved method brought together researchers with vastly different expertise in statistics, computational biology, and immunology,” Dr. Walle writes in the research briefing. “Spectra was a journey of mutual learning, with the shared goal of making complex biology explainable.”

Guiding the Data Analysis

For the paper, the researchers applied Spectra across two breast cancer immunotherapy data sets and a lung cancer atlas, together totaling more than 1.5 million cells from 375 individuals in 21 studies, demonstrating Spectra’s ability to overcome the limitations of traditional analyses at scale.

Spectra gets its power by guiding the data analysis with a body of existing scientific knowledge — libraries of gene programs generated from previous data by experts in their fields. And while this starting knowledge can directly guide single-cell data analysis, the program also adapts to the data at hand, helping to identify new and modified gene programs. (This adaptive property allowed the scientists to uncover a novel cancer invasion program in tumor-associated macrophages related to anti-PD-1 immunotherapy resistance, they note in the paper.)

Spectra’s unique design also takes into account information about the genes that define different cell types, making it more adept at finding gene programs that underlie cellular functions, as opposed to cellular identity.

“Spectra, for example, allows us to separate T cells that are exhausted from the tumor-reactive T cells, which are actively fighting a person’s cancer,” Dr. Pe’er says. “And it helps us to see the differences in gene activation between the two — which is quite challenging to unravel in complex contexts like the tumor microenvironment.”

Additionally, the authors note, the ability to transfer gleanings from one data set directly to another will speed up and streamline discovery, allowing researchers to refine knowledge across single-cell sequencing studies without requiring complex data integration.

Additional Authors, Funding and Disclosures

Additional authors on the paper include Max Land and Tal Nawy, PhD, from the Pe’er Lab at MSK.

The research was funded by grants from the National Cancer Institute Human Tumor Atlas Network (U2C CA233284, U54 CA209975), the MSK Cancer Center Support Grant (P30 CA08748), as well as the Functional Genomics Initiative, the Center for Epigenetics Research, and the Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center at MSK. Additional support was provided by the National Science Foundation and the German Cancer Research Center (DKFZ) Clinician Scientist Program, supported by the Dieter Morszeck Foundation.

Dr. Pe’er reports equity interests in and provision of services for Insitro. Dr. Walle reports stock ownership for Roche, Astra Zeneca, Bayer, Innate Pharma, Fibrogen, Illumina, and 10x Genomics, as well as research funding (not related to this study) from CanVirex AG, Basel Switzerland, and Institut für Klinische Krebsforschung GmbH, Frankfurt, Germany.